功能性运动障碍专科物理治疗的结果:Physio4FMD随机对照试验

IF 4 2区 医学 Q1 HEALTH CARE SCIENCES & SERVICES
Glenn Nielsen, Louise Marston, Rachael Maree Hunter, Alan Carson, Laura H Goldstein, Kate Holt, Teresa C Lee, Marie Le Novere, Jonathan Marsden, Irwin Nazareth, Hayley Noble, Markus Reuber, Jon Stone, Ann-Marie Strudwick, Beatriz Santana Suarez, Mark J Edwards
{"title":"功能性运动障碍专科物理治疗的结果:Physio4FMD随机对照试验","authors":"Glenn Nielsen, Louise Marston, Rachael Maree Hunter, Alan Carson, Laura H Goldstein, Kate Holt, Teresa C Lee, Marie Le Novere, Jonathan Marsden, Irwin Nazareth, Hayley Noble, Markus Reuber, Jon Stone, Ann-Marie Strudwick, Beatriz Santana Suarez, Mark J Edwards","doi":"10.3310/MKAC9495","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Functional motor disorder often causes persistent disabling symptoms that are associated with high healthcare costs. In recent years, specialist physiotherapy, informed by an understanding of functional motor disorder, has emerged as a promising treatment, but there is an absence of evidence of its effectiveness from large randomised controlled trials.</p><p><strong>Methods: </strong>We conducted a pragmatic, multicentre, randomised controlled trial, comparing specialist physiotherapy for functional motor disorder to treatment as usual, which was defined as community neurological physiotherapy. The primary outcome was the Short Form questionnaire-36 items Physical Functioning domain at 12 months (scale range 0-100, with 100 indicating optimum health). The trial was powered to detect a 9-point difference in the primary outcome with 90% power at the 5% level of significance. Secondary domains of measurement included a patient perception of improvement, health-related quality of life, mobility, anxiety, depression and illness perception. We also completed a health economic analysis with the primary aim of calculating the mean incremental cost per quality-adjusted life-year over 12 months. In prespecified analysis plans, we excluded participants from the primary analysis if they were unable to receive their trial-allocated treatment due to COVID-19 lockdown restrictions. Sensitivity analysis explored the impact of this decision.</p><p><strong>Results: </strong>Between 19 October 2018 and 31 January 2022, 355 adults with functional motor disorder were randomised (1 : 1) to specialist physiotherapy (<i>n</i> = 179) and treatment as usual (<i>n</i> = 176). Eighty-nine participants were excluded due to COVID-19 disruptions. Retention for the primary analysis was 90% for both groups, leaving 241 participants in the primary analysis. At 12 months, there was no between-group difference in the primary outcome (adjusted mean difference 3.5, 95% confidence interval -2.3 to 9.3). However, several secondary outcomes favoured specialist physiotherapy, including the participant perception of improvement, Short Form questionnaire-36 items Mental Health domain, confidence in the diagnosis and two subscales (Personal Control and Illness Coherence) of the Revised Illness Perception Questionnaire. There were no differences in the remaining outcomes. At 6 months, the following outcome measures were significantly different, in favour of specialist physiotherapy: participant perception of improvement, the Short Form questionnaire-36 items Physical Role Limitations, Short Form questionnaire-36 items Social Functioning, Short Form questionnaire-36 items Mental Health, EuroQol-5 Dimensions five-level version utility score, confidence in the diagnosis and three subscales (Timeline Cyclical, Personal Control and Treatment Control) of the Revised Illness Perception Questionnaire. No outcomes significantly favoured treatment as usual. In the health economic analysis, the incremental cost per quality-adjusted life-year gained from a health and social care cost perspective was £4133 with an 86% probability that specialist physiotherapy is cost-effective compared to treatment as usual at a cost-effectiveness threshold of £20,000 per quality-adjusted life-year gained. There were no adverse events related to physiotherapy.</p><p><strong>Conclusion: </strong>Specialist physiotherapy was not superior to treatment as usual for the primary outcome, the Short Form questionnaire-36 items Physical Functioning domain at 12 months. However, a number of secondary outcome measures favoured specialist physiotherapy at 6 and 12 months. There is a high probability that specialist physiotherapy is cost-effective.</p><p><strong>Limitations: </strong>Participants in treatment as usual waited longer to start physiotherapy, which resulted in a shorter time between concluding treatment and completing the primary outcome. Most outcome measures, including the primary outcome, were participant reported, which may have been biased by perceptions of the randomised treatment allocation.</p><p><strong>Future work: </strong>Future work should identify or develop more suitable outcome measures for functional motor disorder research, explore who is most likely to benefit from specialist physiotherapy and identify alternative interventions for those unlikely to benefit from this treatment. Additional work is needed to adapt treatment to meet the needs of minority groups and young people.</p><p><strong>Funding: </strong>This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16/31/63.</p>","PeriodicalId":12898,"journal":{"name":"Health technology assessment","volume":"29 34","pages":"1-28"},"PeriodicalIF":4.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12376006/pdf/","citationCount":"0","resultStr":"{\"title\":\"Outcomes of specialist physiotherapy for functional motor disorder: the Physio4FMD RCT.\",\"authors\":\"Glenn Nielsen, Louise Marston, Rachael Maree Hunter, Alan Carson, Laura H Goldstein, Kate Holt, Teresa C Lee, Marie Le Novere, Jonathan Marsden, Irwin Nazareth, Hayley Noble, Markus Reuber, Jon Stone, Ann-Marie Strudwick, Beatriz Santana Suarez, Mark J Edwards\",\"doi\":\"10.3310/MKAC9495\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Functional motor disorder often causes persistent disabling symptoms that are associated with high healthcare costs. In recent years, specialist physiotherapy, informed by an understanding of functional motor disorder, has emerged as a promising treatment, but there is an absence of evidence of its effectiveness from large randomised controlled trials.</p><p><strong>Methods: </strong>We conducted a pragmatic, multicentre, randomised controlled trial, comparing specialist physiotherapy for functional motor disorder to treatment as usual, which was defined as community neurological physiotherapy. The primary outcome was the Short Form questionnaire-36 items Physical Functioning domain at 12 months (scale range 0-100, with 100 indicating optimum health). The trial was powered to detect a 9-point difference in the primary outcome with 90% power at the 5% level of significance. Secondary domains of measurement included a patient perception of improvement, health-related quality of life, mobility, anxiety, depression and illness perception. We also completed a health economic analysis with the primary aim of calculating the mean incremental cost per quality-adjusted life-year over 12 months. In prespecified analysis plans, we excluded participants from the primary analysis if they were unable to receive their trial-allocated treatment due to COVID-19 lockdown restrictions. Sensitivity analysis explored the impact of this decision.</p><p><strong>Results: </strong>Between 19 October 2018 and 31 January 2022, 355 adults with functional motor disorder were randomised (1 : 1) to specialist physiotherapy (<i>n</i> = 179) and treatment as usual (<i>n</i> = 176). Eighty-nine participants were excluded due to COVID-19 disruptions. Retention for the primary analysis was 90% for both groups, leaving 241 participants in the primary analysis. At 12 months, there was no between-group difference in the primary outcome (adjusted mean difference 3.5, 95% confidence interval -2.3 to 9.3). However, several secondary outcomes favoured specialist physiotherapy, including the participant perception of improvement, Short Form questionnaire-36 items Mental Health domain, confidence in the diagnosis and two subscales (Personal Control and Illness Coherence) of the Revised Illness Perception Questionnaire. There were no differences in the remaining outcomes. At 6 months, the following outcome measures were significantly different, in favour of specialist physiotherapy: participant perception of improvement, the Short Form questionnaire-36 items Physical Role Limitations, Short Form questionnaire-36 items Social Functioning, Short Form questionnaire-36 items Mental Health, EuroQol-5 Dimensions five-level version utility score, confidence in the diagnosis and three subscales (Timeline Cyclical, Personal Control and Treatment Control) of the Revised Illness Perception Questionnaire. No outcomes significantly favoured treatment as usual. In the health economic analysis, the incremental cost per quality-adjusted life-year gained from a health and social care cost perspective was £4133 with an 86% probability that specialist physiotherapy is cost-effective compared to treatment as usual at a cost-effectiveness threshold of £20,000 per quality-adjusted life-year gained. There were no adverse events related to physiotherapy.</p><p><strong>Conclusion: </strong>Specialist physiotherapy was not superior to treatment as usual for the primary outcome, the Short Form questionnaire-36 items Physical Functioning domain at 12 months. However, a number of secondary outcome measures favoured specialist physiotherapy at 6 and 12 months. There is a high probability that specialist physiotherapy is cost-effective.</p><p><strong>Limitations: </strong>Participants in treatment as usual waited longer to start physiotherapy, which resulted in a shorter time between concluding treatment and completing the primary outcome. Most outcome measures, including the primary outcome, were participant reported, which may have been biased by perceptions of the randomised treatment allocation.</p><p><strong>Future work: </strong>Future work should identify or develop more suitable outcome measures for functional motor disorder research, explore who is most likely to benefit from specialist physiotherapy and identify alternative interventions for those unlikely to benefit from this treatment. Additional work is needed to adapt treatment to meet the needs of minority groups and young people.</p><p><strong>Funding: </strong>This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16/31/63.</p>\",\"PeriodicalId\":12898,\"journal\":{\"name\":\"Health technology assessment\",\"volume\":\"29 34\",\"pages\":\"1-28\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12376006/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Health technology assessment\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3310/MKAC9495\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health technology assessment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3310/MKAC9495","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

背景:功能性运动障碍通常会导致持续的残疾症状,这些症状与高昂的医疗费用相关。近年来,基于对功能性运动障碍的了解,专业物理疗法已成为一种有希望的治疗方法,但缺乏大型随机对照试验证明其有效性的证据。方法:我们进行了一项实用的、多中心的、随机对照试验,比较功能性运动障碍的专科物理治疗和常规治疗,常规治疗被定义为社区神经物理治疗。主要结果是简短形式问卷-36项12个月的身体功能领域(量表范围0-100,100表示最佳健康)。在5%的显著性水平上,该试验检测到主要结局有9个点的差异,有90%的显著性。次要测量领域包括患者对改善的感知、与健康相关的生活质量、活动能力、焦虑、抑郁和疾病感知。我们还完成了一项健康经济分析,其主要目的是计算12个月内每个质量调整生命年的平均增量成本。在预先指定的分析计划中,如果参与者由于COVID-19封锁限制而无法接受试验分配的治疗,我们将他们排除在初级分析之外。敏感性分析探讨了这一决定的影响。结果:在2018年10月19日至2022年1月31日期间,355名功能性运动障碍成年人被随机(1:1)分配到专科物理治疗组(n = 179)和常规治疗组(n = 176)。89名参与者因COVID-19中断而被排除在外。两组的初步分析保留率均为90%,剩下241名参与者参与了初步分析。在12个月时,主要转归无组间差异(校正平均差为3.5,95%可信区间为-2.3至9.3)。然而,一些次要结果倾向于专科物理治疗,包括参与者对改善的感知,简短问卷-36项心理健康领域,对诊断的信心和修订疾病感知问卷的两个子量表(个人控制和疾病一致性)。其余结果没有差异。在6个月时,以下结果测量有显著差异,有利于专科物理治疗:被试的改善知觉、简式问卷-36项身体角色限制、简式问卷-36项社会功能、简式问卷-36项心理健康、EuroQol-5维度五水平版本效用评分、诊断信心和修订疾病知觉问卷的三个子量表(时间周期、个人控制和治疗控制)。没有结果明显支持常规治疗。在健康经济分析中,从健康和社会护理成本的角度来看,每个质量调整生命年的增量成本为4133英镑,与常规治疗相比,专科物理治疗具有成本效益的可能性为86%,成本效益阈值为每个质量调整生命年获得20,000英镑。没有与物理治疗相关的不良事件。结论:在12个月的36项简短问卷调查中,专家物理治疗并不优于常规治疗。然而,在6个月和12个月时,一些次要结果指标倾向于专科物理治疗。专科物理治疗很可能具有成本效益。局限性:像往常一样接受治疗的参与者等待更长的时间开始物理治疗,这导致结束治疗和完成主要结局之间的时间更短。大多数结果测量,包括主要结果,都是参与者报告的,这可能因随机治疗分配的看法而有偏差。未来的工作:未来的工作应该为功能性运动障碍研究确定或开发更合适的结果测量,探索谁最有可能从专业物理治疗中受益,并为那些不太可能从这种治疗中受益的人确定替代干预措施。需要做更多的工作来调整治疗,以满足少数群体和年轻人的需要。资助:本摘要介绍了由国家卫生与保健研究所(NIHR)卫生技术评估项目资助的独立研究,奖励号为16/31/63。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Outcomes of specialist physiotherapy for functional motor disorder: the Physio4FMD RCT.

Background: Functional motor disorder often causes persistent disabling symptoms that are associated with high healthcare costs. In recent years, specialist physiotherapy, informed by an understanding of functional motor disorder, has emerged as a promising treatment, but there is an absence of evidence of its effectiveness from large randomised controlled trials.

Methods: We conducted a pragmatic, multicentre, randomised controlled trial, comparing specialist physiotherapy for functional motor disorder to treatment as usual, which was defined as community neurological physiotherapy. The primary outcome was the Short Form questionnaire-36 items Physical Functioning domain at 12 months (scale range 0-100, with 100 indicating optimum health). The trial was powered to detect a 9-point difference in the primary outcome with 90% power at the 5% level of significance. Secondary domains of measurement included a patient perception of improvement, health-related quality of life, mobility, anxiety, depression and illness perception. We also completed a health economic analysis with the primary aim of calculating the mean incremental cost per quality-adjusted life-year over 12 months. In prespecified analysis plans, we excluded participants from the primary analysis if they were unable to receive their trial-allocated treatment due to COVID-19 lockdown restrictions. Sensitivity analysis explored the impact of this decision.

Results: Between 19 October 2018 and 31 January 2022, 355 adults with functional motor disorder were randomised (1 : 1) to specialist physiotherapy (n = 179) and treatment as usual (n = 176). Eighty-nine participants were excluded due to COVID-19 disruptions. Retention for the primary analysis was 90% for both groups, leaving 241 participants in the primary analysis. At 12 months, there was no between-group difference in the primary outcome (adjusted mean difference 3.5, 95% confidence interval -2.3 to 9.3). However, several secondary outcomes favoured specialist physiotherapy, including the participant perception of improvement, Short Form questionnaire-36 items Mental Health domain, confidence in the diagnosis and two subscales (Personal Control and Illness Coherence) of the Revised Illness Perception Questionnaire. There were no differences in the remaining outcomes. At 6 months, the following outcome measures were significantly different, in favour of specialist physiotherapy: participant perception of improvement, the Short Form questionnaire-36 items Physical Role Limitations, Short Form questionnaire-36 items Social Functioning, Short Form questionnaire-36 items Mental Health, EuroQol-5 Dimensions five-level version utility score, confidence in the diagnosis and three subscales (Timeline Cyclical, Personal Control and Treatment Control) of the Revised Illness Perception Questionnaire. No outcomes significantly favoured treatment as usual. In the health economic analysis, the incremental cost per quality-adjusted life-year gained from a health and social care cost perspective was £4133 with an 86% probability that specialist physiotherapy is cost-effective compared to treatment as usual at a cost-effectiveness threshold of £20,000 per quality-adjusted life-year gained. There were no adverse events related to physiotherapy.

Conclusion: Specialist physiotherapy was not superior to treatment as usual for the primary outcome, the Short Form questionnaire-36 items Physical Functioning domain at 12 months. However, a number of secondary outcome measures favoured specialist physiotherapy at 6 and 12 months. There is a high probability that specialist physiotherapy is cost-effective.

Limitations: Participants in treatment as usual waited longer to start physiotherapy, which resulted in a shorter time between concluding treatment and completing the primary outcome. Most outcome measures, including the primary outcome, were participant reported, which may have been biased by perceptions of the randomised treatment allocation.

Future work: Future work should identify or develop more suitable outcome measures for functional motor disorder research, explore who is most likely to benefit from specialist physiotherapy and identify alternative interventions for those unlikely to benefit from this treatment. Additional work is needed to adapt treatment to meet the needs of minority groups and young people.

Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16/31/63.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Health technology assessment
Health technology assessment 医学-卫生保健
CiteScore
6.90
自引率
0.00%
发文量
94
审稿时长
>12 weeks
期刊介绍: Health Technology Assessment (HTA) publishes research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信